Endothelial healing rates and quality of COBRA PzF NCS vs. DES to be presented; status update on COBRA REDUCE 14-Day DAPT IDE trial SAN ANTONIO, Texas, Feb. 28, 2018 /PRNewswire/ -- CeloNova BioSciences, Inc. (CeloNova), a global medical device company that offers a family of...
from PR Newswire: //http://ift.tt/2BXaryP
No comments:
Post a Comment